-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Invitation to the grand event2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has been hundreds of millions in half a year, and the oncolytic virus has entered the fast laneYimai New Observation Click on the picture and register now June 10, 2021 /MedClub News/--Following the authorization of the product's rights in India and China to Dr.
Reddy Laboratories and Simcere Pharmaceuticals respectively, Prekin announced the targeting of BCMA CAR-T at the ASCO 2021 annual meeting The latest data of an unregistered clinical study conducted by Cell Injection in Henan Cancer Hospital.
The treatment achieved an objective response rate (ORR) of 88.
2% in the treatment of 34 patients with multiple myeloma, of which 56% of patients Achieve strict complete remission (sCR)
.
The median relapse-free survival (mPFS) was updated to 13.
9 months, and the median time to remission (mDoR) was updated to 13.
3 months
.
In addition, the product has demonstrated very good safety in clinical studies.
Only 1 of 34 patients (2.
9%) had a grade 3 CRS reaction, and the rest were below grade 3; only 1 patient was in CAR- Tocilizumab was used after T treatment to cope with the adverse effects of CRS
.
Dr.
Yao Yi, CMO of Prikin, said that at this ASCO annual meeting, Prikin disclosed the latest efficacy follow-up results obtained in the clinical research carried out by Henan Cancer Hospital.
Its 56% complete remission rate and 13.
9 months’ Both the median relapse-free survival and the median time to remission of 13.
3 months showed very competitive efficacy results
.
With the advancement of the domestic Phase I clinical and international clinical research, I believe this product will bring more exciting news
.
Dr.
Xuhua He, a tenured professor at Duke University Cancer Institute and Duke University Medical Center, said, “In addition to showing very competitive efficacy, Prekin’s BCMA CAR-T also shows excellent safety, especially in its In CAR-T treatment, only a very low-level CRS response appeared
.
In clinical studies of similar foreign CAR-T products, 52% and 79% of patients used tocilizumab to inhibit the CRS response; On the other hand, only 1 patient of Prekin received tocilizumab treatment, and none of the other patients had much CRS response
.
"This latest clinical result was jointly presented by Henan Cancer Hospital and Prekin at the ASCO 2021 annual meeting.
release, ASCO Abstract number: 8025 34 patients were followed up effect diagram (data as of April 2021
.
source: ASCO2021 poster, abstract number 8025) on PRG1801 Puri gold company developed the core product PRG1801 as a target for targeting BCMA , Autologous CAR-T cell drugs based on Nanobody technology
.
This product is aimed at relapsed and refractory multiple myeloma, and has shown extremely superior efficacy and safety in clinical studies
.
Among the 34 patients who have completed the treatment, the objective response rate ORR reached 88% (30/34), and the strict complete remission sCR reached 56% (19/34).
Only 1 patient had Grade 3 CRS, and none of the other patients Serious adverse drug-related reactions, and no neurotoxicity was found
.
At present, the product has obtained the clinical implied license granted by the Drug Evaluation Center of the National Medical Products Administration, and the first phase of clinical trials has been carried out in China; in addition, the rights and interests of this product in China have been authorized by Simcere Pharmaceutical Group, and the rights and interests in India have been authorized.
Authorize Dr.
Ruidi Laboratories Co.
, Ltd.
, and other regions of the world are actively engaged in business development, seeking partners to jointly promote product development
.
About Puruijin Shenzhen Puruijin Biopharmaceutical Co.
, Ltd.
is positioned as a leader in cell and gene therapy drugs with core technologies for industrialization, and is deeply involved in the field of cell and gene therapy drugs.
Shareholders include the National Small and Medium-sized Enterprise Development Fund, Guokejiahe Fund, Haier medical, health Winbond, Hunan health pension industry investment funds
.
The company has a biomedicine R&D and industrialization team with profound academic background and rich practical experience
.
Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen The "CART Cell Quality Control Testing Research and Non-clinical Evaluation Considerations" was released in June 2006, and has participated in the revision of relevant regulations as a member of the expert group
.
The company's product pipeline includes CAR-T, TCR-T, CAR-NK, stem cell drugs, etc.
The indications cover multiple therapeutic fields such as hematological tumors, solid tumors, orthopedics, etc.
, and the only leading innovation that achieves full coverage of immune cell drugs and stem cell drugs Pharmaceutical companies have a wide range and a large market
.
Looking forward to the future, the company will take the research and development of affordable biopharmaceuticals as its mission, further strengthen source research and development, apply for and own a number of high-value new drug pipelines and international patents, maintain and expand its leading edge in the industry, and seize the world's biomedical technology.
Taking the commanding heights, it ranks among the world's leading new biopharmaceutical companies
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to join
.
Reddy Laboratories and Simcere Pharmaceuticals respectively, Prekin announced the targeting of BCMA CAR-T at the ASCO 2021 annual meeting The latest data of an unregistered clinical study conducted by Cell Injection in Henan Cancer Hospital.
The treatment achieved an objective response rate (ORR) of 88.
2% in the treatment of 34 patients with multiple myeloma, of which 56% of patients Achieve strict complete remission (sCR)
.
The median relapse-free survival (mPFS) was updated to 13.
9 months, and the median time to remission (mDoR) was updated to 13.
3 months
.
In addition, the product has demonstrated very good safety in clinical studies.
Only 1 of 34 patients (2.
9%) had a grade 3 CRS reaction, and the rest were below grade 3; only 1 patient was in CAR- Tocilizumab was used after T treatment to cope with the adverse effects of CRS
.
Dr.
Yao Yi, CMO of Prikin, said that at this ASCO annual meeting, Prikin disclosed the latest efficacy follow-up results obtained in the clinical research carried out by Henan Cancer Hospital.
Its 56% complete remission rate and 13.
9 months’ Both the median relapse-free survival and the median time to remission of 13.
3 months showed very competitive efficacy results
.
With the advancement of the domestic Phase I clinical and international clinical research, I believe this product will bring more exciting news
.
Dr.
Xuhua He, a tenured professor at Duke University Cancer Institute and Duke University Medical Center, said, “In addition to showing very competitive efficacy, Prekin’s BCMA CAR-T also shows excellent safety, especially in its In CAR-T treatment, only a very low-level CRS response appeared
.
In clinical studies of similar foreign CAR-T products, 52% and 79% of patients used tocilizumab to inhibit the CRS response; On the other hand, only 1 patient of Prekin received tocilizumab treatment, and none of the other patients had much CRS response
.
"This latest clinical result was jointly presented by Henan Cancer Hospital and Prekin at the ASCO 2021 annual meeting.
release, ASCO Abstract number: 8025 34 patients were followed up effect diagram (data as of April 2021
.
source: ASCO2021 poster, abstract number 8025) on PRG1801 Puri gold company developed the core product PRG1801 as a target for targeting BCMA , Autologous CAR-T cell drugs based on Nanobody technology
.
This product is aimed at relapsed and refractory multiple myeloma, and has shown extremely superior efficacy and safety in clinical studies
.
Among the 34 patients who have completed the treatment, the objective response rate ORR reached 88% (30/34), and the strict complete remission sCR reached 56% (19/34).
Only 1 patient had Grade 3 CRS, and none of the other patients Serious adverse drug-related reactions, and no neurotoxicity was found
.
At present, the product has obtained the clinical implied license granted by the Drug Evaluation Center of the National Medical Products Administration, and the first phase of clinical trials has been carried out in China; in addition, the rights and interests of this product in China have been authorized by Simcere Pharmaceutical Group, and the rights and interests in India have been authorized.
Authorize Dr.
Ruidi Laboratories Co.
, Ltd.
, and other regions of the world are actively engaged in business development, seeking partners to jointly promote product development
.
About Puruijin Shenzhen Puruijin Biopharmaceutical Co.
, Ltd.
is positioned as a leader in cell and gene therapy drugs with core technologies for industrialization, and is deeply involved in the field of cell and gene therapy drugs.
Shareholders include the National Small and Medium-sized Enterprise Development Fund, Guokejiahe Fund, Haier medical, health Winbond, Hunan health pension industry investment funds
.
The company has a biomedicine R&D and industrialization team with profound academic background and rich practical experience
.
Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen Pregene R&D and Manufacturing Center in Shenzhen The "CART Cell Quality Control Testing Research and Non-clinical Evaluation Considerations" was released in June 2006, and has participated in the revision of relevant regulations as a member of the expert group
.
The company's product pipeline includes CAR-T, TCR-T, CAR-NK, stem cell drugs, etc.
The indications cover multiple therapeutic fields such as hematological tumors, solid tumors, orthopedics, etc.
, and the only leading innovation that achieves full coverage of immune cell drugs and stem cell drugs Pharmaceutical companies have a wide range and a large market
.
Looking forward to the future, the company will take the research and development of affordable biopharmaceuticals as its mission, further strengthen source research and development, apply for and own a number of high-value new drug pipelines and international patents, maintain and expand its leading edge in the industry, and seize the world's biomedical technology.
Taking the commanding heights, it ranks among the world's leading new biopharmaceutical companies
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to join
.
